Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Antiviral Res. 2021 Jun 29;193:105125. doi: 10.1016/j.antiviral.2021.105125

Table 4.

Detection of infectious TCRV in deceased, moribund and surviving animals from the prophylactic efficacy experiment

			Infectious TCRV^a
Animal #	Treatment, dose	Status	Serum	Liver	Spleen	Brain
963	ARN-75041, 35 mg/kg	Moribund day 18	ND	ND	ND	ND
972	ARN-75039, 35 mg/kg	Expired day 19	ND	ND	ND	ND
932	ARN-75039, 35 mg/kg	Moribund day 22	ND	ND	ND	ND
945	ARN-75039, 10 mg/kg	Moribund day 22	ND	ND	ND	ND
962	ARN-75041, 35 mg/kg	Moribund day 25	ND	ND	ND	ND
980^b	ARN-75041, 10 mg/kg	Expired day 27	ND	ND	ND	ND
931, 998	ARN-75039, 35 mg/kg	Day 27 survivors	ND, ND	ND, ND	ND, ND	ND, ND
943, 950	ARN-75039, 10 mg/kg	Day 27 survivors	ND, ND	ND, ND	ND, ND	ND, ND
955, 956	ARN-75041, 35 mg/kg	Day 27 survivors	ND, ND	ND, ND	ND, ND	ND, ND
939, 982	ARN-75041, 10 mg/kg	Day 27 survivors	ND, ND	ND, ND	ND, ND	ND, ND
965, 968	Vehicle placebo	Day 27 survivors	2.0, ND	3.3, 5.8	5.5, 6.1	7.3, 6.8
975, 991	Ribavirin, 100 mg/kg/day	Day 27 survivors	2.5, ND	4.3, 3.5	6.1, 5.5	7.1, 7.1

^a

Not detected (ND) or TCRV measured in log₁₀ CCID₅₀/mL

^b

Histopathology consistent with bacterial infection